Numiera Therapeutics Received $2.3 Million Cancer Grant
The Denver-based company will use the NCI funding to advance a clinical trial for a glioblastoma treatment.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Do you trust that government-funded medical research leads to affordable new treatments for patients?
The National Cancer Institute has awarded a $2.3 million grant to Denver-based Numiera Therapeutics. The funding will support an early-phase clinical trial for etomoxir, a potential treatment for recurrent glioblastoma.
Why it matters
Glioblastoma remains a difficult-to-treat form of brain cancer, and this funding enables a critical study to evaluate the safety and pharmacology of etomoxir in patients. The results are expected to lay the groundwork for larger, later-phase trials.
The grant supports a dose-escalation study for etomoxir, a CPT1 inhibitor that has already secured orphan designation for malignant gliomas. Numiera Therapeutics previously completed Phase I safety data for the drug.
The players
Numiera Therapeutics
This Denver-based biotechnology firm focuses on developing novel therapies for complex cancers.
National Cancer Institute
This federal agency is the lead organization for cancer research and training within the United States.
The details
The grant will facilitate a dose-escalation and window-of-opportunity study designed to evaluate how the drug behaves in brain tumor tissue. Researchers aim to establish the maximum tolerated dose while simultaneously seeking an initial signal of efficacy.
Timeline
September 21, 2026: Numiera Therapeutics announced the grant award.
The Big Picture
The project follows the standard path of the National Cancer Institute's SBIR grant program by supporting high-risk, high-reward early-phase clinical research for orphan-designated therapies. This award helps bridge the gap between initial safety testing and the more intensive trials required for regulatory approval.
This clinical trial represents a new potential treatment pathway for patients facing recurrent glioblastoma. Success in this study could eventually expand the options available to those currently managing this aggressive disease.
The takeaway
Advancing brain tumor research requires rigorous study of how drugs interact with human tissue in early clinical phases. Patients and families should discuss the role of clinical trials with their oncology teams when standard treatments prove insufficient.
Further reading
Learn more about the latest research and clinical developments in our Cancer section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that government-funded medical research leads to affordable new treatments for patients?
